Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2018 Jan 28.

Published in final edited form as: J Diabetes Complications. 2016 Oct 7;31(2):449–455. doi: 10.1016/j.jdiacomp.2016.10.003

Table 2.

Measures of maximal and submaximal exercise capacity at baseline and three months

	Placebo (n =12)		Exenatide (n = 11)
	Baseline	3 Months	Baseline	3 Months
VO_2peak (ml/kg/min)	15.4 ± 0.9	16.1 ± 1.1	17.5 ± 1.0	16.6 ± 1.1
VO_2peak (ml/min)	1363 ± 95	1419 ± 119	1783 ± 129	1647 ± 120
RER_peak	1.22 ± 0.3	1.25 ± 0.4	1.19 ± 0.3	1.25 ± 0.2
Peak heart rate (bpm)	134 ± 5	137 ± 5	140 ± 4	138 ± 5
Peak workload (watts)	108 ± 9	110 ± 11	135 ± 12	132 ± 12
VO₂ kinetics τ (sec)	63.3 ± 5.9	67.2 ± 2.7	78.2 ± 6.8	71.4 ± 8.5

Data are Mean ± Standard Error. Peak oxygen consumption: VO_2peak. Respiratory exchange ratio: RER. Beats per minute: bpm.